IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs ALT 803 (Primary) ; ALT 803 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 11 Nov 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2020.
- 27 Aug 2019 Planned End Date changed from 1 Jun 2020 to 1 Oct 2019.
- 06 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.